Daily Stock Analysis, ATOS, Atossa Genetics Inc, priceseries

Atossa Genetics Inc. Daily Stock Analysis
Stock Information
Open
1.55
Close
1.50
High
1.55
Low
1.45
Previous Close
1.52
Daily Price Gain
-0.02
YTD High
1.85
YTD High Date
Feb 9, 2017
YTD Low
1.32
YTD Low Date
Feb 3, 2017
YTD Price Change
0.08
YTD Gain
5.63%
52 Week High
9.60
52 Week High Date
Feb 22, 2016
52 Week Low
1.30
52 Week Low Date
Dec 30, 2016
52 Week Price Change
-7.50
52 Week Gain
-83.33%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Dec 31. 2014
21.45
Jan 2. 2015
22.88
1 Trading Days
6.64%
Link
LONG
Feb 11. 2015
21.15
Feb 24. 2015
24.57
8 Trading Days
16.19%
Link
LONG
Feb 26. 2015
29.85
Feb 27. 2015
31.65
1 Trading Days
6.03%
Link
LONG
Mar 19. 2015
29.40
Mar 24. 2015
31.05
3 Trading Days
5.61%
Link
LONG
Sep 3. 2015
12.45
Sep 16. 2015
13.46
8 Trading Days
8.13%
Link
LONG
Feb 12. 2016
4.65
Feb 24. 2016
6.52
7 Trading Days
40.12%
Link
LONG
Apr 25. 2016
4.65
May 2. 2016
4.95
5 Trading Days
6.45%
Link
LONG
May 26. 2016
4.20
Jun 9. 2016
4.74
9 Trading Days
12.84%
Link
LONG
Oct 31. 2016
1.84
Nov 2. 2016
1.96
2 Trading Days
6.79%
Link
LONG
Nov 29. 2016
2.15
Nov 30. 2016
2.27
1 Trading Days
5.81%
Link
Company Information
Stock Symbol
ATOS
Exchange
NasdaqCM
Company URL
http://www.atossagenetics.com
Company Phone
206.588.0256
CEO
Steven C. Quay
Headquarters
Washington
Business Address
2345 EASTLAKE AVENUE EAST, SUITE 201, SEATTLE, WA 98102
Sector
Equity
Industry Category
Drugs
Industry Group
Diagnostic Substances
CIK
0001488039
About

Atossa Genetics Inc., a clinical-stage pharmaceutical company, focuses on developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions in the United States.

Description

Atossa Genetics Inc., a clinical-stage pharmaceutical company, focuses on developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions in the United States. The company is conducting a Phase II clinical study using microcatheters to deliver fulvestrant as a potential treatment of ductal carcinoma in-situ and breast cancer; and a pharmaceutical program under development is Afimoxifene Topical Gel for the treatment and prevention of hyperplasia of the breast. Atossa Genetics Inc. was founded in 2009 and is headquartered in Seattle, Washington.